Secondary prevention of stroke in patients with atrial fibrillation: Factors influencing the prescription of oral anticoagulation at discharge

被引:26
作者
Deplanque, Dominique [1 ]
Leys, Didier
Parnetti, Lucilla
Schmidt, Reinhold
Ferro, Jose
de Reuck, Jacques
Mas, Jean-Louis
Gallai, Virgilio
机构
[1] Fac Med Lille, Dept Pharmacol, F-59045 Lille, France
[2] Fac Med Lille, Dept Neurol, F-59045 Lille, France
[3] Univ Perugia, Dept Neurosci, I-06100 Perugia, Italy
[4] Graz Univ, Dept Neurol, A-8010 Graz, Austria
[5] Hosp Santa Maria, Dept Neurosci & Mental Hlth, Lisbon, Portugal
[6] Ghent Univ Hosp, Dept Neurol, B-9000 Ghent, Belgium
[7] Hop St Anne, Dept Neurol, F-75674 Paris, France
关键词
stroke; atrial fibrillation; secondary prevention; oral anticoagulation; antiplatelet drugs;
D O I
10.1159/000091546
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Oral anticoagulation (OAC) is the only treatment that has shown a significant benefit to reduce the risk of recurrence in patients with ischemic stroke and nonvalvular atrial fibrillation (NVAF). However, OAC is still underused, even at discharge from neurological centers. The objective of this study was to identify the reasons underlying the prescription of OAC at discharge after an ischemic stroke in patients with NVAF. Methods: We investigated the reasons why ischemic stroke patients with NVAF were not treated with OAC at discharge from 40 centers located in 5 European countries (Austria, Belgium, France, Italy, and Portugal). Results: Of 320 ischemic stroke survivors at discharge, 186 (58.1%) received OAC, while 260 (81.3%) patients were theoretically eligible according to guidelines and the absence of contraindications. There were significant differences between countries and the logistic regression analysis found being already under OAC before stroke, having no leuko-araiosis, having no potential contraindication, being younger than 75 years, being married and suffering from angina pectoris as independent predictors of being discharged under OAC. Conclusion: This study suggests that besides patient-related factors, the prescription of OAC is also significantly influenced by the social environment and national practices. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:372 / 379
页数:8
相关论文
共 36 条
[1]   Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals [J].
Albers, GW ;
Bittar, N ;
Young, L ;
Hattemer, CR ;
Gandhi, AJ ;
Kemp, SM ;
Hall, EA ;
Morton, DJ ;
Yim, J ;
Vlasses, PH .
NEUROLOGY, 1997, 48 (06) :1598-1604
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P1237
[3]   COMPARISON OF STOPPING RULES IN FORWARD STEPWISE REGRESSION [J].
BENDEL, RB ;
AFIFI, AA .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1977, 72 (357) :46-53
[4]  
Blackshear JL, 1996, LANCET, V348, P633
[5]   Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation [J].
Brass, LM ;
Krumholz, HM ;
Scinto, JD ;
Mathur, D ;
Radford, M .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (19) :2093-2100
[6]  
CONNOLLY S, 1994, LANCET, V343, P1509
[7]   Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study [J].
Deplanque, D ;
Leys, D ;
Parnetti, L ;
Schmidt, R ;
Ferro, J ;
De Reuck, J ;
Mas, JL ;
Gallai, V .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) :798-806
[8]   Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? [J].
Deplanque, D ;
Corea, F ;
Arquizan, C ;
Parnetti, L ;
Mas, JL ;
Gallai, V ;
Leys, D .
HEART, 1999, 82 (05) :563-569
[9]   Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? [J].
Evans, A ;
Kalra, L .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (11) :1443-1447
[10]   Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? [J].
Evans, A ;
Perez, I ;
Yu, G ;
Kalra, L .
STROKE, 2001, 32 (12) :2828-2832